Friendly Competition Fosters Progress in Hematologic Malignancies-'These are priceless accomplishments that impact the lives of people.'

摘要

Treatment selection for patients with hematologic malignancies involves a vast knowledge of variations in biology and the rapidly evolving field of systemic therapy development. With options for transplant, chimeric antigen receptor (CAR) T-cell therapy, tyrosine kinase inhibitors (TKIs), and immunotherapy in most tumor types, appropriate therapy selection for a given patient is far from straightforward or standard. To discuss this and emerging breakthroughs, Elias Jabbour, MD, a professor of medicine in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center in Houston, reflected on his body of work and how competition among colleagues motivated his contributions to the field of medicine.